ENDO: IE 3

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/31

encourage image

There's no tags or description

Looks like no tags are added yet.

32 Terms

1
New cards

Understand the pharmacology of estrogen receptors

(Receptor type, activation, effects)

Estrogen receptors (ER)

  • Nuclear receptor superfamily.

  • There are 2 subtypes: ERα and ERβ.

  • ERα and ERβ have different tissue distributions.

Mechanism of estrogen receptor activation

  1. Estrogen enters cell cell by passive diffusion through plasma membrane → binds to the estrogen receptor (ER) → dimerization of ERs → cofactor recruitment → ER dimer–cofactor complex binds to DNA → gene expression.

Effects of estrogen receptor activation on:

  • Uterus, breast tissue, urogenital tract, bone, liver

Estrogen has negative feedback on the hypothalamus/pituitary → decreases FSH and LH.


2
New cards

Explain the mechanism of action of combined & progestins only hormonal.

Combined:

  • Estrogen: Inhibits ovulation

  • Progestin: Thickens cervical mucus


Progestin-Only Contraceptives

Mechanisms:

  • Thickening of cervical mucus

  • Atrophy of the endometrium

  • Hindering implantation

  • Interfere with tubal transport of ova


3
New cards

Key Structural Features of Estrogen Derivatives

Most CHCs contain either:

  • Ethinyl estradiol

  • Estradiol

Important structural/pharmacokinetic features

Ethyne substitution at position 17:

  • ↓ Hepatic metabolism

  • ↑ Bioavailability

Estradiol valerate:

  • Metabolized to estradiol

Mestranol:

  • Metabolized to ethinyl estradiol

Estetrol:

  • Fetal estrogen

  • Lower potency than estradiol

  • Better oral bioavailability

  • Less plasma protein binding

  • Longer half-life compared with estradiol

  • Has a SERM-like profile with antagonist effects in breast tissue and agonist effects in other tissues


4
New cards

Key Structural Features of Progestin Derivatives


Generation

Examples

Androgenic activity

1st (Estranes)

Norethindrone, norethindrone acetate, ethynodiol diacetate

High

2nd (Gonanes)

Levonorgestrel, norgestrel

Moderate

3rd (Newer gonanes)

Desogestrel, etonogestrel, norgestimate

No

4th

Drospirenone, spironolactone

Anti-androgenic

Estrane progestins:

  • Structurally similar to testosterone

  • This contributes to their androgenic activity

  • Have:

    • A keto group at position 3

    • A methyl group at position 17

Desogestrel:

  • Rapidly metabolized in the gut wall and liver to etonogestrel

Norgestimate:

  • Metabolized in the gut and liver to norelgestromin

Drospirenone:

  • Progesterone receptor agonist

  • Testosterone receptor antagonist


5
New cards

CHC: Combined Oral Contraceptives (COCs)

(Ingredients, schedule, formulations)

Contain:

  • Estrogen

  • Progestin

Typically taken:

  • 21 days of active pills

  • 7 days of placebo or no pill

Formulations:

  • Monophasic: fixed estrogen and progestin dose

  • Biphasic: dose increased once during the cycle

  • Triphasic: dose increased twice during the cycle

  • Recently tetraphasic formulations advantage and limitations.


6
New cards

CHC: Transdermal Patch

(Ingredients, schedule, advantages, limitations)

Contains:

  • Ethinyl estradiol

  • Norelgestromin

Schedule:

  • 3 weeks on / 1 week off

Advantages:

  • Better compliance

Limitations:

  • 60% higher dose of estrogen than COCs

  • Possible higher risk of VTE

  • Subcutaneous fat may interfere with absorption

  • Not recommended for individuals >90 kg

  • Cost


7
New cards

Vaginal Ring

(Ingredients, schedule, advantages, limitations)

Contains:

  • Ethinyl estradiol

  • Etonogestrel

Schedule:

  • 3 weeks on / 1 week off

Advantage:

  • Better compliance

Limitations:

  • Comfort level with insertion may be a concern

  • Cost


8
New cards

Progestin Only Pills

(Characteristics, limitation)

Characteristics:

  • No estrogen

  • Lower dose of progestin than COCs

  • No break or placebo pills

  • Light or no menstruation

  • Spotting possible

Major limitation:

  • Compliance is critical

  • Must be taken at the same time daily


9
New cards


Progestin Only Pills

(Characteristics, Limitation)

Characteristics:

  • No estrogen

  • Lower dose of progestin than COCs

  • No break or placebo pills

  • Light or no menstruation

  • Spotting possible

Major limitation:

  • Compliance is critical

  • Must be taken at the same time daily


10
New cards

Progestin Only: Subdermal Implant (Nexplanon)

(Characteristics, Advantages Limitation)

  • Etonogestrel implant

  • Single rod under the skin of the upper arm

  • Releases progestin continuously

  • Provides contraception for 3 years

Advantages:

  • Extremely effective

  • Long-acting

Limitations:

  • Irregular bleeding is common

  • Must be inserted and removed by an HCP


11
New cards

Progestin Only: Depot Injection (DMPA)

(Characteristics, Advantages Limitation)

  • DMPA-IM: given every 12 weeks

  • DMPA-SC: given every 12 weeks

  • SC formulation is less painful and may be self-administered

Advantages:

  • Highly effective

Limitations:

  • Continuous suppression of estrogen → decreased bone density

  • Black Box Warning: not to use for >2 years

  • May take up to 1 year to regain fertility

  • Must return every 3 months for injections


12
New cards

What is emergency contraception

Used to prevent unwanted pregnancy after unprotected or inadequately protected sex.

  • Should be taken as soon as possible

  • Most effective within the first 72 hours

  • Still somewhat effective up to 5 days after intercourse according to the slides


13
New cards

Name the drugs used in emergency contraception and explain their mechanism of action

Levonorgestrel EC

Progestin-only

Examples/formulations:

  • Two-dose formulation: 0.75 mg × 2 tablets

  • Plan B One-Step: single 1.5 mg tablet

MOA:

  • Thickens cervical mucosa → impairs sperm transport

  • Impairs corpus luteum function

  • Inhibits fertilization


Ulipristal (Ella)

  • A selective progesterone receptor modulator (SPRM)

  • Has mixed progesterone agonist and antagonist properties

MOA:

  • Primary mechanism is listed as unknown

  • Consistently shown to inhibit ovulation

  • Other reported but debatable effects involve:

    • Fallopian tube motility

    • Fertilization

    • Implantation

    • Sperm function

  • Prescription only

  • Single dose taken within 120 hours after unprotected intercourse


Copper containing IUDs

  • Spermicidal action of copper


14
New cards

The progestin in combined hormonal contraceptive patch contains ______ and the pill contains ______.

Active metabolite

Prodrug

15
New cards

Food intake is regulated by what 3 organs?

  1. Hypothalamus 2. Gut 3. Adipose tissue


16
New cards

Role of hypothalamus in food intake

Feeding Center

Neuron release:

1. Neuropeptide Y (NPY)+ Agouti-related peptide (AgRP)

2. Orexin

3. Melanin concentrating hormone (MCH)

Satiety Center

Neuron release:

1. Proopiomelanocortin (POMC: Endorphins + α MSH)

2.Cocaine & amphetamine regulated transcript (CART)

3. GLP-1

17
New cards

Role of GI Tract in food intake

Empty Stomach releases ghrelin to stimulate hypothalamus and to initiate hunger

After food intake & digestion → small intestine releases CCK, PYY, GLP-1, Insulin to act on satiety center in hypothalamus

18
New cards

Adipose tissue releases [] and satiety center to release [].

Leptin

POMC

19
New cards

Summary of Regulation of Feeding Behavior

Empty stomach

  • Ghrelin is released → stimulates the hypothalamus.

  • Hypothalamus releases NPY, Orexins, AgRP, and MCH.

  • Result: increased hunger and feeding behavior.

Feeding

  • The small intestine releases CCK, PYY, and GLP-1; insulin also increases.

  • Stimulate the hypothalamus to release POMC and CART.

  • Result: satiety

Leptin

  • Leptin is released from adipose tissue.

  • Stimulate the hypothalamus to release POMC and CART.

  • Result: increased satiety


20
New cards

Obesity Pharmacotherapy

Anti-obesity drugs that may be used for long-term

Peripherally acting drugs

  • Orlistat (Xenical, Alli)

  • Semaglutide (Wegovy), Orforglipron (Foundayo), Tirzepatide (Zepbound)

Centrally acting drugs

  • Phentermine-Topiramate (Qsymia)

  • Bupropion-Naltrexone (Contrave)

Anti-obesity drugs that can be used for short-term only

  • Phentermine


21
New cards

Orlistat (Xenical, Alli) MOA

Inhibits intestinal lipases via acylation at serine 152 of lipases

22
New cards
<p>Name the drugs used in the management of obesity and describe their mechanism of action</p>

Name the drugs used in the management of obesity and describe their mechanism of action

Drug/Class

Molecular Target

Pharmacological Outcome

How It Reduces Obesity

Orlistat

Intestinal lipases

Inhibits breakdown and absorption of dietary fat

↓ Fat absorption → ↓ caloric intake

GLP-1 analogs

GLP-1 receptors

↑ Satiety, ↓ appetite, slows gastric emptying

Eat less due to increased fullness and reduced hunger

Phentermine–Topiramate

Phentermine: ↑ norepinephrine; Topiramate:

Multiple CNS pathways (including Na+ channels, Ca2+ channels, GABA/glutamate)

Suppresses appetite and increases satiety

↓ Hunger and food cravings → ↓ caloric intake

Bupropion–Naltrexone

Bupropion: dopamine/norepinephrine reuptake;

Naltrexone: opioid receptors

Activates appetite-suppressing POMC neurons and prevents inhibitory feedback

↓ Appetite and cravings → ↓ food intake


23
New cards

Explain the pathophysiology of menorrhagia

Menorrhagia = heavy menstrual blood loss (>80 mL) or prolonged bleeding (>7 days).

Causes include:

  • Hematological causes

    • von Willebrand disease → impaired platelet adhesion

    • Thrombocytopenia → decreased platelets

    • Hepatic cirrhosis → impaired synthesis of coagulation factors

  • Uterine causes: fibroids, adenomyosis, polyps, cancer

  • Endocrine: hypothyroidism (rare)

The result is excessive menstrual bleeding, which can lead to anemia and hypovolemia, causing fatigue, lightheadedness, orthostasis, tachycardia, and pallor.

24
New cards

Explain the pathophysiology of dysmenorrhea

Dysmenorrhea = crampy pelvic pain occurring just before or with menstruation, usually lasting 1–3 days.

Primary dysmenorrhea

Occurs with normal pelvic anatomy:

Regressing corpus luteum → ↓ estrogen and progesterone → shedding of uterine lining + influx of inflammatory cells → production of prostaglandins (especially PGE₂ and PGF₂α) and leukotrienes.

  • Prostaglandins → uterine smooth muscle contraction and uterine ischemia → pain

  • Leukotrienes → stimulate nociceptive nerve endings → pain

Secondary dysmenorrhea

Occurs due to pelvic pathology, such as:

  • Cervical stenosis

  • Endometriosis

  • Pelvic infections

  • Polyps

  • Fibroids

  • Pelvic adhesions or outflow obstruction


25
New cards

Explain the pathophysiology of PMS;PMDD

The slides emphasize that estrogen and progesterone play an important role, since PMDD does not occur before menarche, during pregnancy, or after menopause.

Three interconnected theories:

  1. Genetic susceptibility or increased sensitivity of certain brain structures/functions to hormonal changes.

  2. Allopregnanolone, a progesterone metabolite, binds to GABA receptors and interferes with neurons containing the serotonin neurotransmitter.

  3. Estrogen affects serotonin by interfering with its synthesis, metabolism, and autoreceptor-mediated release.

This helps explain the cyclic mood and physical symptoms associated with PMS/PMDD.

26
New cards

Mechanisms of Drugs Used for Menorrhagia

NSAIDs (ibuprofen, naproxen, mefenamic acid)

Inhibit cyclooxygenase (COX) → ↓ uterine prostaglandins → ↓ uterine inflammation and contractions → ↓ bleeding. Menstrual disorders Pathophysio…

Combined hormonal contraceptives (CHCs)

  • Estrogen inhibits FSH and LH through negative feedback.

  • Progestin induces cell differentiation.

  • Overall → inhibition of endometrial tissue proliferation → ↓ prostaglandins → ↓ bleeding. Menstrual disorders Pathophysio…

Levonorgestrel-releasing IUD

Sustained inhibition of endometrial proliferation → endometrial atrophy → less endometrial lining is shed → ↓ bleeding. Menstrual disorders Pathophysio…

Tranexamic acid

An antifibrinolytic and plasmin blocker:

Binds plasminogen and plasmin → prevents plasmin from binding and degrading fibrin → facilitates clotting → ↓ bleeding. Menstrual disorders Pathophysio…

GnRH receptor agonists

  • Initially: stimulate GnRH receptors → ↑ FSH and LH release

  • Continuous stimulation: receptor internalization/downregulation → shutdown of FSH and LH release → menstruation shuts down → ↓ bleeding


27
New cards

Mechanisms of Drugs Used for Dysmenorrhea

NSAIDs

Inhibit prostaglandin synthesis → less uterine contraction/inflammation → less pain.

Combined oral contraceptives

Inhibit endometrial tissue proliferation → ↓ prostaglandins and leukotrienes → less pain.

Levonorgestrel IUD and Depot Medroxyprogesterone Acetate (DMPA)

Cause endometrial atrophy and inhibit prostaglandin/leukotriene generation → less pain.

28
New cards

Explain the pathophysiology of polycystic ovarian syndrome (PCOS)

Main pathway:

↑ GnRH pulse frequency → ↑ LH + ↓ FSH

Increased LH:

↑ LH → increased testosterone synthesis in theca cells → hyperandrogenism

This causes:

  • Acne

  • Hirsutism

  • Baldness

Reduced FSH:

↓ FSH → ↓ estrogen → inhibition of folliculogenesis → no ovulation

Then:

No ovulation → no corpus luteum → lack of progesterone → accumulation of follicles containing unreleased ova → polycystic appearance of the ovaries + oligo/amenorrhea.

Other contributing causes include:

  • Increased CYP17 and 17-βHSD activity → ↑ testosterone synthesis

  • Insulin resistance/hyperinsulinemia → ↑ testosterone synthesis and ↓ sex hormone-binding protein → ↑ free testosterone

  • Obesity → promotes insulin resistance, hyperinsulinemia, and androgen formation Menstrual disorders Pathophysio…


29
New cards

Explain the pathophysiology of endometriosis

Endometriosis = presence of endometrial tissue outside the uterus in the peritoneum.

Possible mechanisms:

Retrograde flow theory

Menstrual fluid and endometrial tissue flow backward through the fallopian tubes into the peritoneal cavity.

Coelomic metaplasia theory

Residual embryonic cells or mesenchymal cells develop/transdifferentiate into endometrial cells, potentially mediated by autoimmune factors.

What causes the damage?

The ectopic endometrial tissue:

Responds to cyclic estrogen changes → bleeds when hormone levels drop → intraperitoneal blood causes WBC influx → chronic cycle of inflammation → ROS formation + lipid peroxidation + scar formation.


Endometrial tissue outside uterus → cyclic hormone response → bleeding → inflammation → ROS/scarring

30
New cards

Understand the regulation of feeding by hypothalamus and GI tract

Food intake is regulated mainly by hypothalamus, gut, adipose tissue through endocrine and neural signals.

Feeding center → Hunger

Satiety center → Fullness

NPY

POMC

AgRP

CART

Orexin

GLP-1

MCH



GI tract:

Empty stomach → ghrelin → hypothalamus → NPY, Orexin, AgRP, MCH → feeding behavior

After food intake and digestion, the small intestine releases:

  • CCK

  • PYY

  • GLP-1

  • Insulin

→ POMC and CART, resulting in satiety. Pharmacology of anti-obesity dr…

Adipose tissue releases leptin:

Leptin → hypothalamus → POMC/CART → satiety

31
New cards

Understand the impact of bariatric surgery on absorption of nutrients and drugs

Why does absorption change

↓ Stomach area

This can lead to:

  • ↓ Food intake

  • ↓ Dietary fat intake

  • ↓ Micronutrient and vitamin intake

  • ↓ Absorption of fat-soluble vitamins

↑ Stomach pH

This can cause:

  • ↓ Calcium absorption

  • ↓ Reduction of Fe³⁺ → Fe²⁺

  • Therefore, ↓ available Fe²⁺/iron absorption


Bypassing the duodenum (Roux-en-Y)

The duodenum is an important site for absorption. Bypassing it can decrease absorption of:

  • Iron

  • Vitamins

  • Micronutrients


Effects on Drug Absorption

  • ↑ Stomach pH may affect drugs that depend on normal GI pH for release.

  • Enteric-coated drugs intended to release in the more basic intestine may be released differently.

  • Roux-en-Y bypasses the duodenum, reducing surface area for absorption.

  • This is especially important for extended-release drugs.


32
New cards

Name the drugs used in the management of obesity and describe their mechanism of action

Drug

Molecular Target

Pharmacological Outcome

How it reduces obesity

Orlistat (Xenical, Alli)

Intestinal lipases

Inhibits lipase activity → prevents breakdown of triglycerides into free fatty acids

↓ Digestion and absorption of dietary fat (also ↓ cholesterol absorption)

GLP-1 analogs

GLP-1 receptors in GI tract and hypothalamus

Delays gastric emptying and suppresses appetite

↑ Feeling of fullness + ↓ food intake/appetite

Phentermine–Topiramate (Qsyima)

Phentermine: NE and dopamine neurotransmission; Topiramate: Na⁺/Ca²⁺ channels, GABA, glutamate pathways

Appetite suppression; topiramate may ↓ appetite and ↑ satiety

↓ Appetite + ↑ satiety → ↓ food intake

Bupropion–Naltrexone (Contrave)

Dopamine/NE pathways and POMC neurons; μ-opioid receptors

Activates POMC-mediated appetite suppression; naltrexone blocks negative feedback

Suppresses appetite → ↓ food intake